WTO LDC patent waiver

  • EU Trade Commissioner Backs LDC Request for TRIPS Exemption for Pharmaceuticals Until Graduation from LDC Status
  • Letter from six NGOs to Obama on the WTO LDC patent waiver negotiation
  • Contrast in privilege: US officials working to block WTO LDC drug patent waiver, and people affected by policy
  • Commentary on the WTO negotiations over waiver of drug patents for Least Developed Countries (LDCs)
  • European Commission supports indefinite exemption for LDCs from WTO IP rules for pharmaceuticals
  • Joint NGO letter to USTR and USPTO: What is the US Position on LDC Pharmaceutical Extension of TRIPS Transition Period?
  • KEI protests USTR opposition to WTO LDC permanent drug patent waiver
  • KEI urges investigation of trade pressures on Least Developed Countries (LDCs) in light of Executive Order 13155
  • Senator Bernie Sanders Asks USTR to Endorse Waiver of WTO Patent Rules for Least Developed Countries
  • Senator Sherrod Brown letter to USTR, supporting permanent waiver of WTO drug patent rules for LDCs
  • Seven Members of House of Representatives Send Letter to USTR Calling For Waiver of WTO Patent Rules for LDCs
  • WTO Decision on Least Developed Country (LDC) Drug Patent Waiver
  • WTO TRIPS Council (February 2015): Bangladesh statement (on behalf of LDC Group)- Extension of the 2016 transitional period
  • WTO TRIPS Council (February 2015): EU statement on LDC extension of transition period for pharmaceutical products
  • WTO TRIPS Council (February 2015): LDC request for extension of the transitional period for pharmaceutical products
  • WTO TRIPS Council (June 2015): LDC Group Presentation on the Extension of the Decision for Pharmaceutical Products
  • WTO TRIPS Council (October 2015) to discuss LDC extension for pharmaceuticals, non-violation, review of the Paragraph 6 system
  • WTO TRIPS Council: World Health Organization issues unequivocal support of LDC transition period for pharmaceutical products
  • Printer-friendly version Send by email Send by email